Novel clinical strategies for the treatment of pancreatic carcinoma

被引:31
作者
Günzburg, WH
Salmons, B
机构
[1] Univ Vet Sci, Inst Virol, A-1210 Vienna, Austria
[2] Austrian Nord Biotherapeut AG, A-1210 Vienna, Austria
基金
美国国家卫生研究院;
关键词
D O I
10.1016/S1471-4914(00)01865-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pancreatic carcinoma ranks as the eighth most frequent type of solid tumour arising worldwide yet it represents the fourth most frequent cause of death, This discrepancy reflects the current lack of effective treatment available for the pancreatic cancer patient and highlights the urgent need for new therapeutic principles in this area,The last five years have seen an increasing number of novel approaches both in the pre-clinical area as well as in clinical trials for pancreatic cancer treatments. This review summarizes these new developments and attempts to rationalize the possibilities available for the patient at the beginning of the new millennium.
引用
收藏
页码:30 / 37
页数:8
相关论文
共 62 条
  • [31] Kamiya Y, 1999, CLIN CANCER RES, V5, p3795S
  • [32] Kelner MJ, 1996, INVEST NEW DRUG, V14, P161
  • [33] ONYX-015: Clinical data are encouraging
    Kirn, D
    Hermiston, T
    McCormick, F
    [J]. NATURE MEDICINE, 1998, 4 (12) : 1341 - 1342
  • [34] TREATMENT OF PATIENTS WITH METASTATIC PANCREATIC AND GASTROINTESTINAL TUMORS WITH THE SOMATOSTATIN ANALOG SANDOSTATIN - A PHASE-II STUDY INCLUDING ENDOCRINE EFFECTS
    KLIJN, JGM
    HOFF, AM
    PLANTING, AST
    VERWEIJ, J
    KOK, T
    LAMBERTS, SWJ
    PORTENGEN, H
    FOEKENS, JA
    [J]. BRITISH JOURNAL OF CANCER, 1990, 62 (04) : 627 - 630
  • [35] Cancer statistics, 1998
    Landis, SH
    Murray, T
    Bolden, S
    Wingo, PA
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 1998, 48 (01) : 6 - +
  • [36] THE P53 TUMOR SUPPRESSOR GENE
    LEVINE, AJ
    MOMAND, J
    FINLAY, CA
    [J]. NATURE, 1991, 351 (6326) : 453 - 456
  • [37] McMorris TC, 1999, DRUG METAB DISPOS, V27, P983
  • [38] Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
    Monia, BP
    Johnston, JF
    Geiger, T
    Muller, M
    Fabbro, D
    [J]. NATURE MEDICINE, 1996, 2 (06) : 668 - 675
  • [39] NCICCTG IND 103: A Phase I and pharmacokinetic (PK) study of the novel L-nucleoside analog troxacitabine (BCH-4556) given every 21 days
    Moore, M
    Belanger, K
    Jolivet, J
    Saker, S
    Wainman, N
    Seymour, L
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S284 - S284
  • [40] Moore M, 1999, CLIN CANCER RES, V5, p3729S